MedPath

Examining the effect of Tranexamic Acid (TXA) on the functional fibrinolysis assay in patients with hereditary bleeding disorder (HBD) compared with healthy controls.

Not Applicable
Not yet recruiting
Conditions
Hereditary Bleeding Disorder (Haemophilia A and B, Von Willebrand disease)
Blood - Clotting disorders
Human Genetics and Inherited Disorders - Other human genetics and inherited disorders
Registration Number
ACTRN12615000311550
Lead Sponsor
Alfred Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not yet recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

One of Hereditary Bleeding Disorder = Haemophilia A, Haemophilia B, or rarer coagulation factor deficiencies {such as factor XI deficiency} and von Willebrand Disease)

Exclusion Criteria

Pregnant or breastfeeding
Past history of thrombosis
Past history of renal disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.